Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Ripasudil is an inhibitor of Rho-associated kinase 1 (ROCK1) and ROCK2 (IC50s = 51 and 19 nM, respectively).1 It is selective for ROCK1 and ROCK2 over protein kinase A catalytic subunit α (PKACα) and PKC (IC50s = 2,100 and >10,000 nM, respectively). Ripasudil (0.4%) reduces intraocular pressure in cynomolgus monkey to a greater extent than the prostaglandin FP receptor agonist latanoprost (Item No. 16812). It increases the outflow facility of the aqueous humor in rabbit eyes when administered in a 0.4% solution. Ripasudil (0.4%) decreases intraocular pressure, retinal ganglion cell death, and thinning of inner retinal layers, as well as improves retinal function, in an excitatory amino acid transporter 1 (EAAT1) knockout mouse model of normal tension glaucoma.2 Formulations containing ripasudil have been used in the treatment of glaucoma and ocular hypertension.
WARNING This product is not for human or veterinary use.
1. Effects of K-
2. Topical ripasudil suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma. Invest. Ophthalmol. Vis. Sci. 59(5), 2080-2089 (2018).